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Abstract 
 
Cultured limbal tissue transplants have become widely used over the last decade as a 
treatment for limbal stem cell deficiency (LSCD). While the number of patients afflicted with 
LSCD in Australia and New Zealand is considered to be relatively low, the impact of this 
disease on quality of life is so severe that the potential efficacy of cultured transplants has 
necessitated investigation. The first Australian trial of cultured limbal transplants was 
undertaken in Brisbane in 2002 with additional trials now having either been completed or 
underway in Sydney and Melbourne respectively. The first New Zealand trial of this 
technology commenced in Auckland in 2008 and is ongoing. Results from these studies have 
been encouraging and potential improvements to the technology are being actively 
investigated at each centre. Nevertheless, low patient numbers combined with emerging 
regulatory requirements for biological therapies in both countries may hamper progress from 
experimental status to routine clinical use. We therefore review the basic biology and 
experimental strategies associated with the use of cultured limbal tissue transplants in 
Australia and New Zealand. In doing so, we aim to encourage informed discussion between 
patients, clinicians, scientists, regulators and industry, on the issues required to advance the 
use of cultured limbal transplants in Australia and New Zealand. Moreover, we propose a 
business model based upon a collaborative network that could be used to maintain access to 
the technology in conjunction with a number of other existing and emerging biological 
therapies for the treatment of eye diseases.  
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Introduction 
Cultured limbal tissue transplants are a specialized type of corneal tissue transplant, used for 
the purpose of treating limbal stem cell deficiency (LSCD)1. While relatively few patients 
stand to benefit from this therapy, cultured limbal transplants represent a significant milestone 
in the development of cellular therapies for repairing the eye. In short, the lessons learned 
from attempts to implement use of cultured limbal tissue transplants, will eventually be 
applied to the manufacture of other cultured tissues, including those for repairing the corneal 
stroma, corneal endothelium and the retinal pigment epithelium (RPE). These lessons relate 
not only to the technical aspects of growing each cell type, but also to emerging regulatory 
requirements for biological therapies and in particular the financial costs of their 
implementation2. Having pioneered the introduction of cultured limbal tissue transplants 
across Australia and New Zealand, we review the current status of this technology within our 
region with the aim to highlighting the lessons learned and challenges ahead on the road to 
achieving routine clinical use of cultured ocular tissue transplants. In particular, we draw 
attention to how the manufacture of these advanced therapies should be funded and by whom 
they should be produced? 
 
The biology of LSCD and cultured limbal transplants 
LSCD is a relatively rare disorder that can arise from a host of diseases or injuries affecting 
the peripheral, or limbal, margin of the cornea. Most commonly, LSCD arises from accidental 
exposure to corrosive chemicals or less commonly from chronic inflammation associated with 
immunological disorders such as Stevens-Johnson syndrome1. The developmental disorder 
aniridia, arising from mutations in the oculogenic PAX6 gene, is also linked to LSCD3. The 
anatomical significance of the limbus is that the progenitor cells required to maintain the 
human corneal epithelium are concentrated within this region4, 5. In the absence of a normal 
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limbus, there are insufficient progenitor cells to renew the corneal surface, and the cornea 
becomes prone to epithelial defects that result in chronic inflammation, scarring and infection. 
Patients afflicted with LSCD, while few in number, suffer from significant pain and vision 
loss, thus necessitating the search for an appropriate therapy. 
 Initial attempts to treat LSCD included transplants of large autologous limbal tissue 
segments for unilateral cases6. In bilateral cases, donor limbal transplants have been used, 
however, they display a high rate of rejection7, presumably owing to the presence of blood 
vessels and immune cells in the limbus. Autologous grafts of limbal tissue are therefore an 
attractive option in cases where a patient has only one eye affected by disease, however, this 
procedure carries the potential risk of inducing LSCD in the patient’s “donor” eye. In 
response to this dilemma, researchers have experimented with the idea of growing patients’ 
own limbal epithelial cells from a small biopsy into a sheet of tissue large enough to be 
applied back onto the entire corneal surface8, 9. Autologous tissue derived from the oral or 
buccal mucosa has been used as a substitute for limbal tissue in the case of bilateral LSCD10.  
Two basic strategies have been used to grow limbal tissue (Figure 1). The first and 
perhaps most widely used technique is to grow the limbal biopsy as an intact tissue explant 
and when sufficient growth is achieved, apply this cultured tissue back onto the ocular 
surface11. Alternatively, others have adopted a technique used for growing sheets of epidermal 
cells for burns patients whereby the biopsied cells are initially dissociated using enzymes, 
then grown to confluency with the aid of a surrogate “dermis” supplied by direct contact with 
a growth-arrested fibroblastic cell line (3T3 cells) derived from mouse embryos8, 9. In either 
case, the basic aim is to produce an epithelial sheet large enough to re-surface the cornea. 
Each approach carries potential risks and benefits. On the one hand, serial propagation of 
limbal epithelial cells in the presence of 3T3 cells produces a large enough quantity of tissue 
to enable multiple transplants without need for further biopsies. While on the other, use of 
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explant cultures avoids the potential health risks associated with using mouse 3T3 cells12 and 
maintains a core culture in contact with the native extracellular matrix (stem cell niche) that 
may yet prove useful for retaining progenitor cell numbers in vitro. 
Despite use of terms such as “corneal stem cell” or “limbal stem cell” transplant, 
cultured limbal tissue consists primarily of immature corneal epithelial cells, however, 
efficacy has been linked to use of cultures in which at least 3% of cells stain brightly for the 
progenitor cell marker ΔNp63α13. Donor amniotic membrane has most often been used as a 
substrate during limbal cell expansion12 and, or transplantation, but fibrin glue14, 15 and 
synthetic materials including contact lenses16 have also been used successfully.  
In some clinics outside Australia and New Zealand, the use of cultured limbal 
transplants is now considered routine and manufacturing is conducted in licensed laboratories 
according to local codes of good manufacturing practice (GMP)2. There are presently no 
licensed manufacturers of cultured limbal tissue transplants within Australia or New Zealand. 
Patients requiring access to this biological therapy may therefore only do so by seeking 
treatment overseas or through recruitment into a local clinical trial. To the best of our 
knowledge, a total of 5 clinical trials of cultured limbal transplants have either been 
completed or are presently underway across Australia and New Zealand. The key details of 
these trials are summarized in Table 1 and a case series for one of the recent trials is 
summarized in Table 2.  
 
 
Clinical trials in Australia and New Zealand 
Brisbane 
Two clinical trials of cultured limbal tissue transplants have been conducted in Brisbane. The 
first trial was led by Dr Andrew Apel between 2002 and 2003 at the Royal Brisbane & 
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Women’s Hospital, and the Queensland Eye Hospital. Three scientists were involved in this 
study: Associate Professor Damien Harkin, a cell biologist and academic at the Queensland 
University of Technology (QUT), assisted by Dr Zeke Barnard (while a PhD student), and Mr 
Peter Gillies, who was at that time responsible for growing experimental sheets of skin cells 
for burns patients at the Australian Red Cross Blood Service (ARCBS) in Brisbane. 
Consumables costs were borne by Harkin’s research grants and labor costs were donated as 
in-kind support from QUT (Harkin) and ARCBS (Gillies). Manufacturing was conducted 
within a dedicated cell culture facility at ARCBS. After performing a preliminary assessment 
of conditions for culturing limbal epithelial cells17, the team adopted the skin cell culture 
protocols where dissociated epithelial cells are co-cultured with 3T3 cells. The cultures were 
expanded for approximately 2 weeks with the aid of 3T3 cells before sub-culturing to 
confluency on donor amniotic membrane supplied by the Lions Eye Bank in Melbourne. 
Excess cells were frozen in liquid nitrogen and were successfully used to generate additional 
cultures for transplant on amniotic membrane. Five patients were treated during this trial, two 
of which received a second transplant using cells that had been frozen following the initial 
expansion. The clinical outcomes for one patient have been reported as a case study18. 
Notably, this clinical trial was terminated prematurely owing to closure of the skin cell culture 
laboratory at ARCBS, thus emphasizing the importance of securing on-going access to a 
dedicated manufacturing facility. 
A second clinical trial was conducted in Brisbane in 2005 (CTN No. 093/2005), led by 
Professor Lawrie Hirst and Professor Ivan Schwab at the Queensland Eye Institute, with Drs 
Harkin and Barnard again providing a support role. This study attempted cultivation of 
dissociated cells from biopsies using a commercial serum-free medium found in earlier 
preliminary studies to support limbal epithelial cell growth (Defined Keratinocyte Serum-Free 
Medium from Invitrogen). Moreover, an attempt was made to apply cultured cells to the 
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ocular surface while suspended in autologous fibrin glue14. Significantly, no other research 
projects involving cell culture were being conducted at this time thus enabling the cell culture 
laboratory at the QEI to be dedicated to trial manufacturing. Unfortunately, this trial was 
abandoned after recruitment of one patient owing to poor stability of the autologous fibrin 
clot containing cultured cells within 24-hours following transplantation to the ocular surface. 
No further trials have been conducted at this facility as the laboratory is now heavily used for 
numerous non-clinical projects.  
 
Sydney   
A team in Sydney has completed the world’s first trial of limbal tissue transplants cultured 
and transplanted while attached to contact lenses (ACTRN12607000211460)19. The idea for 
this approach originated in 2006 from laboratory research conducted by Associate Professor 
Nick Di Girolamo (School of Medical Sciences, University of New South Wales) who 
demonstrated that a variety of cell types from the ocular surface could be propagated on a 
particular type of therapeutic contact lens19. Following this proof-of-concept, a pilot clinical 
study was initiated in late 2007 using autologous cells from patients with limbal stem cell 
deficiency (LSCD) cultured on a contact lens in culture medium supplemented with the 
patient’s own serum19. Clinical Professor Stephanie Watson conducted the trial at the 
Department of Ophthalmology, Prince of Wales Hospital and Sydney Eye Hospital with 3 
patients. Two of the patients had LSCD following treatment for conjunctival melanoma and 
one patient had the genetic form of LSCD, aniridia. Cultured cells were phenotyped to ensure 
that progenitor cells were included in the transplanted cells. The successful results of this 
study were published in the journal Transplantation in 200916. The advantages of this system 
are (i) ‘self’ cells are cultured from a small biopsy (~1 mm2), (ii) cells are expanded from a 
tissue known to harbor stem cells as well as niche support factors and signals, (iii) cells are 
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propagated in patient’s own serum (used to promote adherence of progenitor cells) without 
xenogeneic components thereby reducing the risk of rejection and eliminating the need for 
immunosuppressive therapy, (iv) cells are not sub-cultivated, i.e. they are not exposed to 
enzyme solutions, hence their phenotype is less likely to change during the short culture 
period (10-14 days), (v) cells are cultured on an FDA-approved therapeutic contact lens which 
acts as a substrate, carrier, and protective shield during the attachment, growth and transfer 
phase, and (vi) the procedure is relatively simple, with a short treatment period, a rapid 
recovery phase and the potential to be repeated if necessary. The shortcomings for the 
procedure are (i) the location of the limbal biopsy is difficult standardize between patients, (ii) 
cells are cultured on an artificial surface, and (iii) the transplanted autologous cells are 
difficult to track, knowledge of their whereabouts would be important to inform how many 
transplanted cells survive and for how long. Funding to conduct a larger clinical trial in 
Sydney was obtained in 2010 from the Australian Stem Cell Centre. Patients with limbal stem 
cell failure were treated by Clinical Professor Stephanie Watson at the Sydney Eye Hospital 
with cells cultured in the laboratory of Associate Professor Nick Di Girolamo at UNSW. The 
trial was completed late in 2011 and the data is currently being analysed.  
During the course of these clinical trials, Associate Professor Di Girolamo and 
Clinical Professor Stephanie Watson were supported by an NH&MRC Career Development 
Award and a Health Practitioner Training Fellowship respectively. In addition the University 
of NSW provided 3 years of funding towards progressing this work. The Australian Stem Cell 
Centre was closed in 2011 leaving a gap in potential sources of funding for stem cell 
researchers. The current work of this team focuses on understanding how their procedure 
restores the ocular surface and how it can be optimized. Animal models exist that will 
facilitate this work. Indeed, independent groups in Singapore and Melbourne are currently 
using a modification of the contact lens-based procedure in an appropriate animal model to 
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examine how bandage contact lenses can be used as a cell substrate and delivery device for 
the treatment severe ocular surface disease20. 
 
Melbourne 
A prospective interventional study of cultured limbal tissue transplants is currently underway 
in Melbourne. The study lacks intervention and comparison groups required to meet the 
International Committee of Medical Journal Editors (ICMJE) definition of a clinical trial. All 
patients meeting selection criteria have been offered the intervention. The study is being 
conducted in two phases, to assess safety and efficacy, and is led by ophthalmic surgeon 
Associate Professor Mark Daniell. Cultures were initially grown by Dr David Francis and Dr 
Trent Roydhouse (while undertaking studies towards a Masters of Surgery degree), but for the 
last two years cells have been grown by senior research assistant and postgraduate research 
student Mr Karl Brown. Dr Keren Abberton of the O’Brien Institute is also providing on-
going scientific input to this study. Cultures are being grown using an explant method, based 
closely on that developed at the LV Prasad Eye Institute in Hyderabad21. Limbal explants 
have been sourced from cadaveric donor tissue, living related donors, or the patient’s contra-
lateral eye. Use of autologous cultivated oral mucosal epithelial transplantation (COMET) as 
a substitute for limbal tissue has also been attempted according to established methods10. 
Explant tissues from all sources are cultured on denuded donor amniotic membrane, 
originally supplied by the Lions Eye Bank in Melbourne, but currently sourced from the New 
Zealand National Eye Bank. The culture medium is supplemented with the patient’s own 
serum and is free from animal products. Using this technique, confluent sheets of limbal 
epithelium are being achieved within 7-14 days. During the preliminary phase of this trial to 
assess safety, 6 patients were treated over 5 years to 2011. Phase two is ongoing, with ethics 
approval to treat up to 12 patients. This work is funded by Professor Daniell’s departmental 
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funds, supplemented by additional funding received from the Ophthalmic Research Institute 
of Australia (ORIA), Australia-India Strategic Research Fund (AISRF) and the University of 
Melbourne. 
 
Auckland  
Traditional, autologous, contra-lateral sourced, limbal tissue “stem” cell transplants have been 
used by the ophthalmologists in the University of Auckland corneal service for nearly twenty 
years. However, in a manner similar to the program in Melbourne (vide supra), a prospective 
interventional study of cultured limbal tissue transplants has been underway in Auckland 
since 2008. Due to the relative rarity of the conditions that lead to stem cell failure, and 
consequent need for limbal cultured transplants, the study lacks a control arm although all 
patients received maximum medical and standard surgical interventions for several 
weeks/months prior to meeting selection criteria for inclusion (i.e. limbal stem cell failure 
with significant corneal epithelial compromise resistant to standard therapies).  
To date 6 eyes of 5 patients have been treated by ex-vivo expanded epithelial cells on 
amniotic membrane, closely following the protocol established in Melbourne by Associate 
Professor Mark Daniell and Mr Karl Brown. In five subjects limbal tissue was available from 
the opposite eye and for one patient (patient E) no healthy limbal tissue was available, 
therefore a mucosal biopsy was obtained from the internal surface of the patient’s lower lip. 
All cultures were grown by Ms Jane McGhee with support from Associate Professor Trevor 
Sherwin in the Tissue Culture Suite, Department of Ophthalmology, New Zealand National 
Eye Centre, Faculty of Medical and Health Sciences, University of Auckland. This work was 
funded by departmental funds and supporting grants obtained by Professors McGhee and 
Sherwin.  
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In all patients bar one, a small biopsy (approx 1 x 1mm) of limbal tissue was taken 
from the healthy superior limbus of the undamaged/less damaged eye. The biopsy was placed 
directly onto amniotic membrane supplied and prepared by the New Zealand National Eye 
Bank. The amniotic membrane was stretched over an open-ended cylinder with basement 
membrane uppermost such that the tissue biopsy and culture medium were contained within 
the cylinder. After applying the biopsy, it was left for 5 minutes to settle with no 
predetermined orientation and then over laid with 400µl of culture medium (DMEM/F12 
(Gibco) supplemented with 10% autologous serum, insulin-transferrin-selenium (Sigma), L-
glutamine and antibiotics (Gibco)). After overnight culture at 37˚ and 5% CO2, a further 1ml 
of medium was added. Thereafter, spent medium was replaced every three days.  
Cell outgrowth from the explanted tissue was observed either by inverted microscopy 
and/or dark field microscopy. Spent medium was collected in order to monitor for bacterial 
contamination. No contamination was detected. Epithelial outgrowth and confluence was 
achieved in all explants (typically by day 16) with the end point (day of surgery) being no 
later than day 21. At this time point, cultures were transported in culture medium to the Eye 
Theatre at Greenlane Hospital, Auckland District Health Board for the planned intervention. 
All subjects underwent superficial keratectomy and focal or complete removal of 
scarred limbal tissue. The 18-20 mm diameter amniotic membrane was carefully positioned 
with the cell culture innermost and the membrane was secured with 12 peripheral sutures of 
10/0 Vicryl. In patients A and B, a penetrating keratoplasty (PKP) was performed at a later 
date when the ocular surface had stabilized. In case A* this was associated with a second 
limbal cell transplant to accompany the corneal transplant (Figure 2). In patient C, a 
simultaneous PKP was performed in a subject whose main indication was relief of pain in an 
eye with a highly unstable ocular surface. All limbal cell transplants were successful in terms 
of producing a stable, comfortable ocular surface and clear cornea (Table 2) with variable 
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improvement of visual acuity. Unfortunately, the single case of expanded buccal mucosa in an 
extremely dry, Stevens Johnson Syndrome eye, failed within 2 months. 
 
Future access to treatment in Australia and New Zealand 
Once any new therapy has been determined safe and beneficial to patients, it will generally 
become available on a more routine basis. Cultured limbal tissue transplants have been shown 
to be safe and while there remains room for improvement, the bulk of clinical data from both 
within and outside the region indicates that these treatments reduce pain, improve cosmesis 
and can partially restore vision1, 13, 22, 23. Notably, best overall results are often obtained when 
used in conjunction with conventional surgical treatments such as penetrating keratoplasty (as 
shown previously by Harkin et al. (2004)18 and presently in Table 2 and Figure 2). Thus it 
seems logical that this technology should in time advance beyond its experimental status in 
Australia and New Zealand, however, there are a number of issues to be resolved before 
achieving this goal. 
A number of hurdles need to be overcome to progress the use of cultured limbal tissue 
transplants in Australia and New Zealand. These include resources, time and effort required to 
establish and maintain a licensed manufacturing facility2. According to the recently updated 
regulatory framework for biological therapies developed by the Therapeutic Goods 
Administration of Australia (TGA), cultured limbal tissue transplants seem likely to be 
classified as a category 3 biological (owing to ex vivo expansion of cells and potential use of 
digestive enzymes that may alter their properties). Steps required in the licensing of category 
3 biologicals include preparation of a dossier outlining in detail all processes used during 
manufacture ranging from sourcing of materials used, up until methods of final product 
storage and delivery back to the patient. Preparation of the dossier is anticipated to be a 
particularly time-consuming process. The dossier is submitted to TGA for evaluation to 
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ensure compliance with default manufacturing standards. Moreover, the facility in which the 
biological is produced must hold a current TGA manufacturing license that is issued after 
demonstration of compliance with manufacturing principles including those outlined in the 
Australian Code of GMP for Human Blood and Tissues. The fees associated with these 
regulatory requirements are summarized in Table 3. In order to alleviate these costs, the 
Australian government has committed funds during the first three years of the new regulatory 
framework (31st May 2011 until 31st May 2014) to cover the direct regulatory costs associated 
with implementation, but only in the case of publicly funded organizations and not-for-profit 
hospital supply units. Thus there is a clear incentive for organizations that fall within this 
category to galvanize their efforts during this window of opportunity. The regulatory 
landscape in New Zealand seems destined to follow a similar path given the merger between 
Australian (Therapeutic Goods Administration) and New Zealand (Medsafe) regulatory 
authorities currently in progress. 
Assuming that the initial regulatory fees can be waived, there remain additional costs 
associated with establishing and maintaining the required laboratory infrastructure, as well as 
paying staff salaries. In particular, a salary would need to be provided to support the 
application process to the regulator. Closely coupled with these considerations is the fact that 
patients with LSCD are considered less common in Australia and New Zealand, thus making 
it potentially unfeasible from an economic perspective to establish and maintain a laboratory 
solely for the purpose of treating this disease. By comparison, Mesoblast Ltd 
(http://www.mesoblast.com/), a company that specializes in the manufacture of cultured bone 
marrow mesenchymal stromal cells, is marketing this biological therapy for a range of 
common health conditions including musculoskeletal defects and cardiovascular disease. 
Significant lessons can also be gained by considering the history of cultured skin tissue 
transplants in Australia and New Zealand, which after several years of manufacture by not-
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for-profit organizations and hospital supply units, are now required to be produced within 
licensed facilities24, 25.  
In considering the above, we propose that a dedicated not-for-profit facility should be 
established to serve the needs of LSCD patients in Australia, New Zealand as well as patients 
from other countries within the region. This facility could also be responsible for 
manufacturing processed donor amniotic membrane, which in addition to being used as a 
therapeutic bandage for the treatment of corneal diseases, could potentially be incorporated 
into standardized protocols for culturing limbal tissue. Looking further ahead, the techniques 
that are currently being developed in Australia and New Zealand for the ex vivo expansion of 
corneal endothelial cells26 and limbal stromal cells27 could also be incorporated into the list of 
manufactured products thus greatly increasing the number of patients who would receive 
benefit from this facility. Alternatively, given the costs and logistics of patient transport, it 
may well prove more feasible to maintain laboratories in multiple centres, with a reduction in 
manufacturing costs achieved through adoption of standardized protocols throughout 
Australia and New Zealand. In doing so, the technology could be administered through a 
similar collaborative network as currently exists for the supply of donor eye tissue in 
Australia and New Zealand7. As such, we would further propose that the Eye Bank 
Association of Australia and New Zealand (EBAANZ), that represents the interests of eye 
banks in these countries, could play a vital role in facilitating initial discussions across state 
and national borders on this issue.  
 
Conclusions 
Cultured limbal tissue transplants have proven to be an effective step forward in the treatment 
of LSCD. Several clinics within Australia and New Zealand have developed the expertise 
required to cultivate limbal tissue for transplantation under the auspices of clinical trials. 
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Translation of this therapy from experimental status to routine use, however, will require 
manufacture within a GMP-licensed facility. The economic logistics of this endeavor will 
most likely necessitate a collaborative approach within the region and perhaps can be 
facilitated by combining with other orphaned and emerging therapies for ocular diseases. In 
the short term, we propose that the existing network of eye tissue banks within the region 
(EBANZ), together with the Royal Australian and New Zealand College of Ophthalmologists 
(RANZCO) and affiliated research scientists, should establish a standardized protocol for the 
manufacture of cultured limbal tissue transplants in Australia and New Zealand. 
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Figures 
 
 
 
Figure 1. Demonstration of the two basic strategies used for growing cultured limbal tissue 
transplants. (A) Explant technique: a small biopsy of patient limbal tissue is grown intact as 
an explant while attached to some form of support substrate. The image displays epithelial 
cell outgrowth beyond the edge of the explant (dark centre) after two days culture on a 
Lotrafilcon ATM contact lens in culture medium supplemented with 10% (v/v) patient serum. 
The patient received the culture after approximately 10 days, at which time the entire surface 
of the contact lens was covered with epithelial cells. (B) Ex-vivo expansion in presence of 
murine 3T3 cells: a similar sized biopsy to the one shown in part A is digested using enzymes 
to create a cell suspension then seeded into culture dishes containing growth-arrested murine 
3T3 cells. The image displays an island of limbal epithelial cells (surrounded by 3T3 cells) 
that is typical of that observed within the first 7 days of culture. Using this approach, 
approximately 10 million cells are available for transplantation within 2 weeks (sufficient for 
at least 5 treatments).  
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Figure 2. Example of clinical outcome for patient treated with cultured limbal tissue 
transplant (Auckland study Patient A*: use in conjunction with penetrating keratoplasty). (A) 
Appearance of eye demonstrating extensive scarring and vascularisation of cornea following 
an alkaline chemical injury (BCVA = “counting fingers” only. (B) Appearance of eye 
immediately following performing penetrating keratoplasty (PKP) in conjunction with an 
overlying graft of cultured limbal tissue grown on amniotic membrane. (C) Appearance of 
same eye 12 months following combined grafting procedure (BCVA = 6/12).  
 
Tables 
Table 1. Summary of clinical trials in Australia and New Zealand examining the use of cultured limbal tissue transplants. 
Study Manufacturing 
facility 
Funding sources Culture method Source of 
tissue 
Substrate Trial status No. of  
patients 
References 
Apel & 
Harkin 2002-
2003 
ARCBS1 in 
Brisbane 
QUT2, ARCBS, 
Royal Brisbane and 
Women’s Hospital 
Research Foundation 
Dissociated co-
culture with 
murine 3T3 cells. 
Autologous Amniotic 
membrane 
Complete 5 18  
Hirst, Schwab 
& Harkin 
2006 
Queensland Eye 
Institute 
Research to Prevent 
Blindness, UC Davis, 
Queensland Eye 
Institute, QUT 
Dissociated 
culture grown in 
commercial 
serum-free 
medium 
Autologous Autologous 
fibrin glue 
(Cryoseal)  
Complete 1 - 
Watson & Di 
Girolamo 
1. 2007 
2. 2010-2011 
School of 
Medical 
Sciences 
UNSW3 
1. School of Medical 
Sciences, UNSW 
2. Australian Stem 
Cell Centre 
Explant cultures 
grown on contact 
lenses 
Autologous Contact 
lens 
Complete 3 
13 
16 
- 
Daniell, 
Abberton & 
Brown 
2007-present 
Centre for Eye 
Research 
Australia and 
the O’Brien 
Institute 
University of 
Melbourne, ORIA4 & 
AISRF5. 
Explant cultures 
grown on 
amniotic 
membrane 
Autologous/
allogeneic 
limbus and 
autologous 
oral mucosa 
Amniotic 
membrane 
In progress 6+ - 
McGhee, 
Sherwin & 
McGhee 
2008-present 
Department of 
Ophthalmology 
University of 
Auckland 
Department of 
Ophthalmology 
University of 
Auckland 
Explant cultures 
grown on 
amniotic 
membrane 
Autologous 
limbus or 
oral mucosa  
Amniotic 
membrane 
In progress 6+ 
(refer to 
Table 2) 
- 
  
1Australian Red Cross Blood Service. 2Queensland University of Technology. 3University of New South Wales. 4Ophthalmic Research Institute 
of Australia. 5Australia-India Strategic Research Fund. 
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Table 2: Case series of cultured tissue transplants for the treatment of LSCD (Auckland study). Details of six eyes of five subjects (A to E) with 
M:F ratio 4:1, treated for limbal stem cell deficiency by autologous, ex vivo expanded, limbal cell transplants on human amniotic membrane 
(except case E which used expanded buccal mucosa). Pre-operative best-corrected visual acuity (BCVA) was between 6/24 to “Perception of 
Light” (P of L) and the majority of eyes achieved improved vision following surgery. One eye (patient E) had limited visual potential due to 
retinal disease. Four of five patients also underwent penetrating keratoplasty (PKP) being time separated in two cases (A* and B). One case had 
two stem cell expansions on amniotic membrane (A and A*). Four of five eyes maintained restoration and stability of the ocular surface at 9-36 
months. (CF = counting fingers vision). 
Patient Gender
/Age 
Cause of 
LSCD 
Indication Pre-op 
BCVA 
Post-op 
BCVA 
General outcome Follow-up 
(Months) 
A M /37 Alkali injury 
 
Ocular surface restoration CF CF Stable corneal surface 6 
A* M / 38 Alkali injury 
 
 
Ocular surface restoration plus PKP CF 6/12 Clear cornea (refer to 
Figure 2). 
30  
B M / 23 Firework: 
chemical & 
thermal 
Ocular surface restoration plus PKP 6/36 6/9 Clear cornea 24 
C F / 46 PKP/RD & 
multiple 
operations 
Ocular surface restoration plus PKP CF 6/36 Clear cornea 12 
D M / 42 Thermal injury 
boiling water 
Ocular surface restoration 6/24 6/18 Clear cornea 9 
E M / 63 Steven-
Johnson 
syndrome 
Ocular surface restoration plus PKP 
NB: buccal mucosal tissue used in 
absence of available limbal tissue. 
P of L P of L Failed 9 
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Table 3. Summary of regulatory fees associated with applying for and maintaining a TGA-licensed facility to manufacture a category 3 
biological such as cultured limbal tissue transplants (adapted from http://www.tga.gov.au/about/fees.htm). Additional application and evaluation 
fees are associated for minor and major amendments to the manufacturing protocol. Not-for-profit organizations and hospital supply units have 
until to 31st May 2014 to apply for a fee exemption. A similar pricing structure seems likely to be adopted in NZ in view of current merger of 
regulatory authorities to create the Australia New Zealand Therapeutic Products Agency (ANZTPA).  
 
Description Fee1 
Evaluation of dossier for a Class 3 biological $120,000 
Application for manufacturing license $900 
Application for Inclusion of a class 1, 2, 3, 4 biological in the ARTG2 $900 
Domestic initial manufacturing audit $17,990 
Annual charge for inclusion of a Class 2,3 or 4 biological in the ARTG $5,550 
Domestic subsequent manufacturing audit $13,500 
 
1Australian dollars. 2Australian Register of Therapeutic Goods.  
